(INCY) Incyte - Ratings and Ratios

Incyte Corporation (NASDAQ:INCY) is a biopharmaceutical company focused on advancing innovative therapies for serious diseases. The company specializes in hematology/oncology and inflammation/autoimmunity, with a robust portfolio of approved and investigational drugs.

Their lead product, JAKAFI (ruxolitinib), is a JAK1/JAK2 inhibitor approved for myelofibrosis, polycythemia vera, and steroid-refractory graft-versus-host disease. They also market MONJUVI (tafasitamab) for diffuse large B-cell lymphoma, PEMAZYRE (pemigatinib) as a FGFR kinase inhibitor for certain cancers, and ICLUSIG (ponatinib) for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Additionally, they offer ZYNYZ (retifanlimab-dlwr) for Merkel cell carcinoma and OPZELURA cream for atopic dermatitis.

The company has an extensive clinical pipeline, including retifanlimab in Phase 3 trials for anal canal cancer and non-small cell lung cancer, and axatilimab in Phase 2 for chronic graft-versus-host disease. Other notable candidates include INCA033989, INCB160058, and INCB99280, targeting various solid tumors and inflammatory conditions.

Incyte has established strategic collaborations with major pharmaceutical companies, including Novartis, Lilly, Agenus, and MacroGenics, to accelerate drug development and commercialization. They also have a partnership with China Medical System Holdings for the development of povorcitinib in certain territories.

With a market cap of ~$13.5 billion, Incyte operates with a P/E ratio of 466.73 and a forward P/E of 11.57, reflecting its growth potential. The company distributes its products through specialty pharmacies, hospitals, and wholesalers globally.

Originally founded as Incyte Genomics in 1991, the company rebranded as Incyte Corporation in 2003, signaling its shift from genomics research to therapeutic development. Today, it stands as a key player in the biopharma industry, balancing commercial success with a strong emphasis on R&D.